The WHO recommended two new treatments against the coronavirus: which are

The World Health Organization (WHO) officially recommended two new treatments against Covid-19 so that they are applied in very precise cases, taking the total of these drugs To five.

In a report published in the medical journal The BMJ, WHO experts suggested a treatment based on synthetic antibodies, the Sotrovimab, Y a medicine that is usually used against rheumatoid polyarthritis, the Baricitinib.

“When both are available” you have to choose which of the two to use “based on cost, availability and the experience of healthcare professionals”they stated. However, it should be clarified that these medicines They are not intended for just any patient.

Sotrovimab is recommended for patients who contracted Covid-19 without severity, but are at high risk of hospitalization. Its benefit in patients who are not at risk is too low.

As soon as to Baricitinib, it should be used in “patients suffering from a severe or critical Covid”, and it must be administered “combined with corticosteroids”. In these patients, this “improves the survival rate and reduces the need for mechanical ventilation.”

Up to now, WHO recommended three treatments: the synthetic antibodies sold under the name of “Ronapreve”, since September 2021; a type of medicine called “Antagonists of interleukin 6” (the Tocilizumab and the Sarilumab), since July 2021; and the systematic corticosteroids for critically ill patients, from September 2020.

Sotrovimab affects the same type of patients as Ronapreve. “Its effectiveness against new variants such as omicron it is still uncertain ”, clarified – nevertheless – the WHO experts.

They also said that Baricitinib “has the same effects” as interleukin 6 antagonists and should be administered to the same type of patient. This treatment, now recommended by the entity for the coronavirus, It belongs to a family of medicines called “Janus kinase inhibitors” and is used against rheumatoid arthritis, an autoimmune disease.

However, the specialists clarified that the other drugs of this family (Ruxolitinib and Tofacitinib) should not be used against Covid-19 due to the lack of data on its efficacy and side effects.

The WHO regularly updates its treatment recommendations against Covid, based on clinical trials conducted with different types of patients.

However, the therapeutic arsenal continues to be reduced. In the last few months, The WHO rejected the use of several treatments: the injection of plasma from patients cured of Covid-19, Ivermectin or Hydroxychloroquine.

AFP Agency

Leave a Reply